RU2781248C1 - Specialized food product for dietic therapeutic and dietic preventive nutrition and method of its application - Google Patents

Abstract

FIELD: food industry.

SUBSTANCE: the invention relates to the food industry. A specialized food product for dietary therapeutic and dietary preventive nutrition is proposed, which is a multicomponent dry mixture of essential nutrients containing phenolic compounds in an amount of 5 to 200% of their physiological requirement for adults, dietary fiber in an amount of 5 up to 200% of their physiological requirements for adults, L-carnitine, in an amount from 5 to 200% of their physiological requirements for adults, coenzyme Q10 in an amount from 5 to 200% of their physiological requirements for adults.

EFFECT: invention is aimed at restoring body functions disturbed or lost as a result of a disease, preventing these disorders, as well as at increasing the body's adaptive capabilities.

13 cl, 15 tbl, 19 ex

Description

Technical field

The present invention relates to the food industry, to products of dietary therapeutic and dietary preventive nutrition, in particular, to a specialized food product for dietary therapeutic and dietary preventive nutrition, which is a multicomponent dry mixture of essential nutrients and a method for its use.

The invention can be used for dietary therapeutic and dietary preventive nutrition of adults in medical organizations, social security institutions and workers employed in jobs with harmful working conditions as a component of the preparation of ready-made meals.

Prior Art

It is known that at the modern pace of life, human consumption of the required amount of micronutrients, including biologically active substances, can only be ensured by taking complex preparations that include vitamins, minerals, as well as other micronutrients or essential substances, such as amino acids, unsaturated fatty acids, provitamins, etc., therefore, such drugs are becoming more common.

Physiological norms for the consumption of micronutrients necessary for the human body, including biologically active substances, are established by Rospotrebnadzor on the basis of large-scale epidemiological studies and scientific data.

The composition of medical nutrition in hospitals of medical institutions includes protein mixtures, vitamin-mineral complexes, which have a certain chemical and ingredient composition and a proven therapeutic effect. However, the specialized food products used do not ensure the enrichment of the diet of a sick or convalescent patient with essential biologically active substances with established chemical structure and physiological action, present in food in small quantities (milligrams or micrograms) and playing a proven role in maintaining health, performing the functions of exogenous metabolism regulators.

Known dry mix for a sports drink (see, for example, RU 2428063 C1, publ. 10.09.2011). The mixture includes 47-55 wt.% maltodextrin, 0.6-0.9 wt.% L-carnitine, 6-8 wt.% fructooligosaccharides and gum arabic, 0.12-0.15 wt.% vitamin complex, 4-7 wt.% natural sea salt, 0.7-0.9 wt.% calcium lactate, 0.5-0.9 wt.% magnesium sulfate, 0.5-0.7 wt.% potassium chloride, 0.3- 6.2 wt.% flavor and fructose - the rest up to 100%. The proposed mixture allows you to increase the nutritional value of the mixture, replenish the supply of salts and vitamins in the cells, lost with sweat during training, the athlete, thereby ensuring the restoration of electrolyte balance, increase endurance and reduce fatigue.

Said dry mix for a sports drink cannot be used for dietary therapeutic and dietary preventive nutrition, since it is not balanced and cannot ensure the enrichment of the diet of a sick or convalescent patient with an optimal set of both macro- and micronutrients, including essential biologically active substances. In addition, its therapeutic and / or preventive effect on diseases has not been proven.

A vitamin-mineral complex is known, a method for its manufacture and a method for its administration (see, for example, RU 2250049 C9, publ. individual overdoses of certain vitamins.

The vitamin-mineral complex is an established set of components - vitamins, macro- and microelements. These components are contained in at least two compositions, which are a mixture of components, the compositions are intended to be taken separately in time. One of the compositions is made as a preparative form, the properties of which, which determine the rate of its decay in the human body, are different from the similar properties of preparative forms representing other compositions of the vitamin-mineral complex. The preparative form of each composition is determined by the place in the human digestive tract of preparation for the assimilation of at least two components included in it. A particular component is assigned to a particular composition based on certain conditions, taking into account the minimization of negative interactions of the composition components in terms of joint storage and assimilation by the human body. The compositions mainly combine components that synergistically affect the assimilation of each other by the human body. The components are also combined taking into account the requirement of the unity of the place in the human digestive tract, preparation for the assimilation of at least two components. The composition components are supplemented with at least one technological material. At the same time, if different compositions of the complex are represented by preparative forms of the same type, then various dyes are included in the mentioned compositions, which makes it possible to identify the compositions.

The method of taking the vitamin-mineral complex includes taking the compositions orally separately in time. At the same time, the vitamin-mineral complex is taken depending on the preparative form of the composition, the composition of the components (fat-soluble, water-soluble) and taking into account the nature of the food taken (abundant, non-abundant, fatty, non-greasy). EFFECT: invention allows to reduce the cost of vitamin-mineral complexes and increase their shelf life, provides optimal conditions for the absorption of biologically active substances by the body.

The specified vitamin-mineral complex cannot be used in standard diets for dietary therapeutic and dietary preventive nutrition and in the nutrition of social service recipients in social protection institutions, since it must be prescribed strictly individually, for medical reasons, taking into account possible allergic reactions and idiosyncrasy to certain vitamins and minerals, especially in children.

A known product of dietary and preventive nutrition (see, for example, RU 2403802C1, publ. 20.11.2010), which is a mixture filled with liquid, made from a composition containing dried grain of durum wheat, heat-treated by the explosion method, oatmeal, flax seeds , milk thistle, grape seeds, as well as crushed particles of clover grass, raspberry leaves, lingonberries and green tea, hawthorn, rose hips, red currant berries or leaves and walnut kernels. The components are in the following ratio, g / 100 g of the finished dry product: durum wheat grain 55.0-57.0, oatmeal 15.0-17.0, flax seeds 4.0-4.2, milk thistle 4.0- 4.2, grape seed 1.1-1.7, clover grass 1.0-1.3, raspberry leaves 1.0-1.3, lingonberry leaves 2.0-2.1, hawthorn fruits 2.0- 2.1, rose hips 4.0-4.2, green tea leaves 2.0-2.1, red currant berries or leaves 2.0-2.1, walnut kernels 2.0-2.1. EFFECT: invention makes it possible to obtain a product that has a prophylactic effect on the human body.

The specified dietary and preventive food product cannot be used as a component of the preparation of ready-made meals in standard therapeutic diets for dietary therapeutic and dietary preventive nutrition, since it is an independent dish that can only be used individually in personalized diets prescribed in a hospital by the attending physician.

As a well-known technical solution, an instant functional food product for correcting nutritional status disorders is also considered (see, for example, RU 2525338 C1, publ. 08/10/2014), which contains protein, carbohydrate and fat components, vitamin and mineral premix, dietary fiber, flavoring , aromatic and other additives. As a protein component, chicken protein hydrolyzate is used, enriched with skimmed cow's milk protein. As a carbohydrate component - a mixture of mono- or disaccharide with a polysaccharide. The vitamin-mineral premix additionally contains a biologically active substance - a mixture of selenium, molybdenum and chromium. A functional food product allows you to expand the range of instant functional food products, has an increased nutritional and biological value and can be used in the nutrition of people with overweight, for nutritional support for people with a low body mass index, to increase the adaptive capacity of the body.

The specified instant functional food product for the correction of eating disorders cannot be used for dietary therapeutic and dietary preventive nutrition, since, according to the description, it can only be used in the nutrition of people with overweight, for nutritional support for people with a low body mass index and is not a source of biologically active substances.

A specialized food product is known for maintaining the reserve forces of the body (see, for example, RU 2737196 C1), containing fish oil, linseed oil, dihydroquercetin, lipoic acid, eicosapentaenoic acid, docosahexaenoic acid, alpha-linolenic acid, phosphorus, copper, potassium, vitamins A, E and selenium at a given ratio of components. The method for obtaining a specialized food product is characterized by the fact that a semi-finished product of a liposome with dihydroquercetin is prepared by dissolving dihydroquercetin in water when heated to 61 ° C in a homogenizer, then lecithin is added, stirred for an hour, then homogenized for 5 minutes until a homogeneous mass, then dried at a temperature of 72 °C. After that, a mixture for encapsulation is prepared by initially dosing fish oil, linseed oil, lipoic acid, then liposomes with dihydroquercetin are added, then eicosapentaenoic, docosahexaenoic and alpha-linolenic acids, phosphorus, copper, potassium are dosed, then mixed and homogenized for 10 minutes. At the final stage, vitamin A, E, selenium are dosed sequentially into the cooled mixture, then a gelatin solution is prepared by dosing auxiliary components in the following sequence: purified water, glycerin, gelatin. Soft gelatin capsules are obtained from a ready solution of gelatin and a mixture for encapsulation on a capsule machine of the SGM 1010 type, then the capsules are dried in drying tunnels for 53 hours and unloaded.

The specified specialized food product for maintaining the reserve forces of the body cannot be used for dietary therapeutic and dietary preventive nutrition, since, according to the description, it can only be used in the nutrition of people with overweight, for nutritional support of people with a low body mass index and is not a source with established chemical structure and physiological action, present in food in small quantities (milligrams or micrograms) and playing a proven role in maintaining health, acting as exogenous regulators of metabolism.

The essence of the invention

The present invention is directed to the creation of a specialized food product for dietary therapeutic and dietary preventive nutrition, which is a multicomponent dry mixture of essential nutrients and a method for its use, ensuring the achievement of a technical result, which consists in restoring disturbed or lost body functions as a result of a disease, preventing these disorders, and also to increase the adaptive capabilities of the body, which is achieved by introducing essential biologically active substances into the diet in an amount of 5 to 200% of their norm of physiological need for adults.

The specified technical result is achieved by the fact that a specialized food product, which is a multicomponent dry mixture of essential nutrients, is used as a component in the preparation of ready-made meals for dietary therapeutic and dietary preventive nutrition.

The specified technical result is achieved by the fact that the proposed specialized food product for dietary therapeutic and dietary preventive nutrition, which is a multicomponent dry mixture of essential nutrients, contains

phenolic compounds selected from the group consisting of phenolic acids and/or flavonoids and/or polymeric phenolic compounds and/or stilbenes in an amount of 5 to 200% of their normal physiological requirements for adults;

dietary fiber selected from the group consisting of cellulose and/or hemicellulose and/or chitin and/or chitosan and/or β-glucans and/or gum and/or inulin and/or oligofructose and/ or fructooligosaccharides, and/or lignin, and/or pectins, and/or polydextrose, and/or resistant dextins, and/or oligofructose, and/or fructooligosaccharides, and/or resistant starches, in an amount of 5 to 200% of their normal physiological needs for adults;

L-carnitine, in an amount of 5 to 200% of their normal physiological requirements for adults;

Coenzyme Q10 in an amount of 5 to 200% of their normal physiological requirements for adults.

At the same time, phenolic compounds selected from the group consisting of phenolic acids and/or flavonoids and/or polymeric phenolic compounds and/or stilbenes are contained in an amount of from 0.2 to 1548 mg.

Dietary fibers selected from the group consisting of cellulose, hemicellulose and/or chitin and/or chitosan and/or β-glucans and/or gum and/or inulin and/or oligofructose and/or fructooligosaccharides, and/or lignin and/or pectins and/or polydextrose and/or resistant dextins and/or resistant starches are contained in an amount of 1.25 to 50 g.

L-carnitine, contained in an amount of 15 to 600 mg;

Coenzyme Q10 is contained in an amount of 1.5 to 60 mg.

It is advisable that hydroxybenzoic acid in an amount of 5 to 100 mg and/or hydroxycinnamic acid in an amount of 20 to 400 mg be used as phenolic acids in a specialized food product .

It is advisable that flavonols in an amount of 3 to 60 mg and/or flavanones in an amount of 3 to 60 mg and/or flavan-3-ols in an amount of 20 to 400 mg be used as flavonoids in a specialized food product, and/ or flavones in an amount of 1 to 20 mg, and/or anthocyanins in an amount of 5 to 100 mg, and/or isoflavones in an amount of 0.2 to 4 mg.

It is advisable that condensed and hydrolysable tannins in the amount of 20 to 400 mg be used as polymeric phenolic compounds in the specialized food product.

It is advisable that the specialized food product contains stilbenes in an amount of 0.2 to 4 mg.

A specialized food product can be used for dietary therapeutic and dietary preventive nutrition of adults.

A specialized food product may additionally contain compounds of a protein and/or carbohydrate and/or fatty nature, and/or vitamins and vitamin-like compounds, and/or minerals, and/or other biologically active substances, and/or nutritional supplements, and/ or flavors and/or processing aids, including those selected from the group of antioxidants and/or defoamers and/or sweeteners and/or fillers and/or carriers and/or stabilizers and/or anti-caking agents, and/ or naturally present in the raw material source of the biologically active substance that is part of the product.

The specialized food product can be used in standard, special and personalized diets for the nutrition of adult patients in medical organizations.

This technical result is achieved by the fact that a method for preparing dietary therapeutic and dietary preventive nutrition is proposed, characterized in that a specialized food product according to the invention is introduced during the preparation of dietary therapeutic and dietary preventive nutrition in an amount that ensures the introduction into the daily diet from 5 to 200% the norms of the physiological need for essential biologically active substances - phenolic compounds, dietary fiber, L-carnitine and coenzyme Q10, then mixed in the mass of the dish.

The specified technical result is achieved by the fact that the use of a specialized food product for the preparation of dishes for dietary therapeutic and dietary preventive nutrition is proposed.

Detailed description of the preferred embodiments of the invention

The proposed specialized food product for dietary therapeutic and dietary preventive nutrition is a multicomponent dry mixture of essential nutrients used to prepare ready-made meals for dietary therapeutic and dietary preventive nutrition, and contains:

phenolic compounds selected from the group consisting of phenolic acids, flavonoids, polymeric phenolic compounds, stilbenes in an amount of 0.2 to 1548 mg;

dietary fiber selected from the group consisting of cellulose, hemicellulose, chitin, chitosan, β-glucans, gum, inulin, oligofructose, fructooligosaccharides, lignin, pectins, polydextrose, resistant dextins, resistant starches, in an amount of 1.25 to 50 g ;

L-carnitine, in an amount of 15 to 600 mg;

Coenzyme Q10 in an amount of 1.5 to 60 mg.

The specialized food product contains, as a source of phenolic acids, a dry extract of at least one component selected from the group consisting of:

blueberries, leaves and fruits of apples, green coffee beans, green tea, leaves and fruits of cherries, rose hips, echinacea purpurea, radiola rosea, pomegranate, eleutherococcus, magnolia vine, wheat, artichoke, lettuce, cocoa beans, onions (husks), black radish , blueberries, plums, cherries, kiwi, cinnamon, coffee, mango, citrus, rice, corn, oats, red wine, potatoes, apricot, barley, malt, rye, eucommia, basket willow, milk thistle, lemon balm, thyme, basil, anise, rosemary, tarragon, marjoram, sage, tomato, peach, cranberry, rapeseed, white cabbage, red cabbage, turnip, radish, broccoli, chicory, dandelion, elecampane, rudbeckia, dioica nettle, common spruce, canadian goldenrod, carrot, viburnum , bamboo sprouts, asparagus, beets, Chinese cabbage, thyme.

The specialized food product contains, as a source of flavonoids, a dry extract of at least one component selected from the group consisting of: red grapes, green tea, black tea, citrus, leek, pomegranate, strawberry, blackberry, blackcurrant, blueberry, black elderberry , cranberries, celery, parsley, wheat, millet, tomatoes, cherries, peaches, plums, red onions, red radishes, black beans, eggplant, red cabbage, olives, sweet potatoes (yam), buckwheat, milk thistle, St. John's wort, red wine, apples, spruce bark, cocoa, soybeans, ginkgo biloba, golden mustache, oats, passionflower, Chinese magnolia vine, white tea, clover, quince, turmeric, hawthorn, Japanese Sophora, mint, bergamot, pomegranate, hops, cinquefoil, thyme, oregano, sorghum, dill, beans, alfalfa, red beans, honeysuckle, nectarines, prunes.

The specialized food product contains, as a source of polymeric phenolic compounds, a dry extract of at least one component selected from the group consisting of: grape seeds, red wine, skin, stems and pulp of grapes, black currant, black elderberry, chokeberry (chokeberry) , blueberries, blueberries, cocoa, black tea, green tea, sea pine, apples, plums, pomegranate, cranberries, raspberries, peaches, mangosteens, pears, rose hips, dogwood, honeysuckle, crows, hibiscus, prunes, viburnum, carrots, beans, beans, nectarines, dates, bananas, sorghum, peas, walnuts, cashews, persimmons, acorns, chestnuts, rhubarb, vanilla, tarragon, hazelnuts, pecans, bearberry, thick-leaved bergenia.

The specialized food product contains, as a source of stilbenes, a dry extract of at least one component selected from the group consisting of: skin, stems and pulp of grapes, mulberries, red wine, peanuts, hops, cocoa, Japanese knotweed, blackberries, peanut butter, pistachios , almonds, blueberries, cranberries, strawberries, carob, blueberries, jackfruit, cranberries.

The specialized food product contains, as a source of dietary fiber, a dry form of at least one component selected from the group consisting of:

- cellulose and hemicellulose, represented by at least one component selected from the group consisting of microcrystalline cotton cellulose, bamboo fiber, psyllium, apple fiber, linen fiber, pumpkin fiber, rye fiber, beet fiber, oat fiber, corn fiber, pea fibers ;

- chitin and chitosan obtained from marine invertebrates;

- β-glucans represented by at least one component selected from the group consisting of oat β-glucan, brewer's yeast β-glucan, shiitake mushrooms, reishi mushrooms (lacquered tinder fungus), oyster mushrooms, algae;

- gums represented by at least one component selected from the group consisting of gellan gum, guar gum, gum arabic, xanthan gum, locust bean gum;

- inulin, oligofructose and fructooligosaccharides represented by at least one component selected from the group consisting of Jerusalem artichoke, chicory, finished forms of fructooligosaccharides;

- lignin represented by at least one component selected from the group consisting of: bamboo fiber, psyllium;

- pectins represented by at least one component selected from the group consisting of apple fiber, citrus pectin, black currant fiber;

- polydextrose;

- resistant dextrins, represented by at least one component selected from the group consisting of water-soluble corn fibers, ready-made substances of resistant dextrins;

- resistant starches represented by at least one component selected from the group consisting of potato starch, tapioca starch, corn starch, oat starch, buckwheat starch, bean flour, unripe banana flour.

The specialty food product contains dry forms of L-carnitine and/or acetyl-L-carnitine as a source of L-carnitine.

The specialty food product contains the dry form of coenzyme Q10 as a source of coenzyme Q10.

These dry extracts are mixed in the required proportions to obtain a finished specialized food product. A specialized food product is used in the preparation of dietary therapeutic and dietary preventive nutrition, for which it is introduced during the preparation of dishes in an amount that ensures the introduction into the daily diet from 5 to 200% of the norm of the physiological need for essential biologically active substances - phenolic compounds, dietary fiber, L -carnitine and coenzyme Q10. The product is added 2-3 minutes before the readiness of a liquid or viscous dish, for example, in soups, compotes, kissels, cereals, or at the beginning of the cooking process, for example, in stews, casseroles, pastries, etc., then it is thoroughly mixed in weight of the dish.

Distinctive features of a specialized food product, which is a multicomponent dry mixture of essential nutrients, are, on the one hand, ensuring an adequate level of consumption of essential biologically active substances in the standard diets of adults undergoing inpatient treatment in medical organizations, in the diets of people living in social protection institutions , diets of workers employed in jobs with harmful working conditions, on the other hand, the presence of biologically active ingredients ensures the correction of a complex of functional and metabolic disorders in diseases and pathological conditions, increases the protective physiological functions of the body, reduces the impact on the body of harmful environmental factors, activates processes of binding and excretion of unfavorable metabolic products from the body.

The technical effect is achieved due to the following.

Due to the content of phenolic acids represented by hydroxybenzoic and/or hydroxycinnamic acids, the specialized food product reduces the risk of developing neurodegenerative diseases, insulin resistance, type 2 diabetes mellitus, cardiovascular diseases, dyslipidemia, renal dysfunction and obesity due to antioxidant activity, helps to reduce glucose absorption and modulation of hormone secretion in the intestine, has a cytoprotective effect against low-density lipoprotein oxidation.

Due to the content of flavonoids in its composition, represented by flavanones and/or flavan-3-ols, and/or flavones, and/or anthocyanins, and/or isoflavonoids, a specialized food product has a multifaceted effect in maintaining health, and they perform the functions of exogenous regulators metabolism - they have the ability to serve as traps for free radicals, as well as chelate metal ions involved in peroxidation; reduce the synthesis of cytokines in adipose tissue and, thus, prevent the release of free fatty acids into the blood, leading to the development of insulin resistance and type 2 diabetes; interact with various targets in the cell, including the transcription factor NF-kB, which controls the expression of immune response and apoptosis genes. Antioxidant, antiradical, anti-inflammatory, antiallergic, vasodilatory, vaso- and cardioprotective, hypocholesterolemic, antibacterial, antiviral, choleretic, diuretic, cytoprotective properties of various groups of flavonoids contained in the proposed specialized food product are shown.

Due to the content of polymeric phenolic compounds represented by condensed and hydrolysable tannins, the specialized food product has an antioxidant, anti-inflammatory, antimicrobial, adaptogenic, memory-improving effect, promotes liver regeneration, inhibits hepatocarciogenesis, stimulates the central nervous system, improves cognitive functions, mental and physical performance in adverse climatic conditions, with high physical exertion and under stress.

The specialized food product, due to the content of stilbenes in its composition, has an antioxidant effect due to the ability to inhibit lipid oxidation, has an antitumor effect that manifests itself in various parts of the cell life cycle (apoptosis and autophagy; the cycle of cell division and their differentiation; cellular redox homeostasis, etc.). ), indirectly affect sirtuin proteins, slowing down the process of cell aging.

Specialized food product due to the content in its composition of dietary fibers represented by cellulose and/or hemicellulose, and/or chitin, and/or chitosan, and/or β-glucan, and/or gums, and/or inulin, and/or oligofructose , and/or fructooligosaccharides, and/or lignin, and/or pectins, and/or polydextrose, and/or resistant dextins, and/or resistant starches, has numerous physiological and metabolic effects, playing a key role in the formation of fecal masses and the regulation of motility intestines; contributing to the accelerated removal of foreign substances, endo- and exotoxins, salts of heavy metals from the body. Dietary fibers have a prebiotic effect, promoting the growth and development of normal human intestinal microflora, including bifidobacteria, which is accompanied by a decrease in chyme pH and suppression of bacterial formation of potential carcinogens, an increase in butyrate formation and protection of intestinal mucosal cells from malignant degeneration, etc. Hypocholesterolemic effect of dietary fibers due to their ability to bind, increase the excretion and accelerate the metabolism of bile acids, slow down the absorption of cholesterol in the small intestine, reduce the absorption of lipids by increasing their excretion, inhibit the synthesis of cholesterol in the liver under the influence of short-chain fatty acids formed during the fermentation of soluble foods in the large intestine fibers. Dietary fiber has a hypoglycemic effect due to a slowdown in gastric emptying, a decrease in the availability of starch for digestive enzymes, and a decrease in glucose absorption in the small intestine.

A specialized food product, due to the content of L-carnitine in its composition, helps to preserve the integrity of membranes, stabilize the immune system, economically use glycogen and glucose reserves during prolonged intense exercise, participates in the metabolism of ketone bodies and cholines, inhibits the formation of lactate, and has immunostimulating properties. The use of L-carnitine helps to reduce the signs of physical and mental overstrain, stimulates performance, has a cardio-, hepato- and neuroprotective effect.

A specialized food product, due to the content of coenzyme Q10 in its composition, takes part in energy metabolism and contractile activity of the heart muscle, in the transfer of electrons in the respiratory chain of mitochondria, oxidative phosphorylation, is necessary for the functioning of the immune system, has antioxidant properties, and the ability to increase cell tolerance to hypoxia.

Below are examples of the use of the proposed specialized food product.

Example 1

A specialized food product, which is a multicomponent dry mixture of essential nutrients, provides 50% of the daily norm of the physiological need for essential nutrients as part of the main version of the standard diet and the standard diet with mechanical and chemical sparing of adults undergoing inpatient treatment in medical organizations, the diet of social recipients. services in a stationary form in social protection institutions, the diet of workers employed in work with harmful working conditions.

Ingredient Content phenolic acids,
- hydroxybenzoic acids, mg
- hydroxycinnamic acids, mg 25
100 flavonoids,
- flavonols, mg
- flavanones, mg
- flavan-3-ols, mg
- flavones, mg
- anthocyanins, mg
- isoflavonoids, mg fifteen
fifteen
100
5
25
one Polymeric phenolic compounds, including condensed and hydrolysable tannins, mg 100 Stilbenes, mg one Dietary fiber, g:
cellulose,
hemicellulose,
chitin 12.5 L-carnitine, mg 150 Coenzyme Q10, mg fifteen

Example 2

A specialized food product, which is a multicomponent dry mixture of essential nutrients, provides 75% of the daily norm of the physiological need of essential nutrients as part of a high-protein version of the standard diet of adults undergoing inpatient treatment in medical organizations, the diet of social service recipients in a stationary form in social protection institutions, diet of workers employed in work with harmful working conditions.

Ingredient Content phenolic acids,
- hydroxybenzoic acids, mg
- hydroxycinnamic acids, mg 37.5
125 flavonoids,
- flavonols, mg
- flavanones, mg
- flavan-3-ols, mg
- flavones, mg
- anthocyanins, mg
- isoflavonoids, mg 22.5
22.5
125
7.5
37.5
1.25 Polymeric phenolic compounds, including condensed and hydrolysable tannins, mg 125 Stilbenes, mg 1.25 Dietary fiber, g:
chitin,
chitosan,
β-glucan 22.5 L-carnitine, mg 225 Coenzyme Q10, mg 22.5

Example 3

A specialized food product, which is a multicomponent dry mixture of essential nutrients, provides 5% of the daily norm of the physiological need of essential nutrients as part of a low-protein version of the standard diet of adults undergoing inpatient treatment in medical organizations, the diet of social service recipients in a stationary form in social protection institutions, diet of workers employed in work with harmful working conditions.

Ingredient Content phenolic acids,
- hydroxybenzoic acids, mg
- hydroxycinnamic acids, mg 2.5
ten flavonoids,
- flavonols, mg
- flavanones, mg
- flavan-3-ols, mg
- flavones, mg
- anthocyanins, mg
- isoflavonoids, mg 1.5
1.5
ten
0.5
2.5
0.1 Polymeric phenolic compounds, including condensed and hydrolysable tannins, mg ten Stilbenes, mg 0.1 Dietary fiber, g:
β-glucan 1.25 L-carnitine, mg fifteen Coenzyme Q10, mg 1.5

Example 4

A specialized food product, which is a multicomponent dry mixture of essential nutrients, provides 25% of the daily norm of the physiological need of essential nutrients as part of a low-calorie version of the standard diet of adults undergoing inpatient treatment in medical organizations, the diet of social service recipients in a stationary form in social protection institutions, diet of workers employed in work with harmful working conditions.

Ingredient Content phenolic acids,
- hydroxybenzoic acids, mg
- hydroxycinnamic acids, mg 12.5
fifty flavonoids,
- flavonols, mg
- flavanones, mg
- flavan-3-ols, mg
- flavones, mg
- anthocyanins, mg
- isoflavonoids, mg 7.5
7.5
fifty
2.5
12.5
0.5 Polymeric phenolic compounds, including condensed and hydrolysable tannins, mg fifty Stilbenes, mg 0.5 Dietary fiber, g:
inulin,
oligofructose,
fructooligosaccharide 6.25 L-carnitine, mg 75 Coenzyme Q10, mg 7.5

Example 5

A specialized food product, which is a multicomponent dry mixture of essential nutrients, provides 100% of the daily norm of the physiological need of essential nutrients as part of a high-calorie version of the standard diet of adults undergoing inpatient treatment in medical organizations, the diet of social service recipients in a stationary form in social protection institutions, diet of workers employed in work with harmful working conditions.

Ingredient Content phenolic acids,
- hydroxybenzoic acids, mg
- hydroxycinnamic acids, mg fifty
200 flavonoids,
- flavonols, mg
- flavanones, mg
- flavan-3-ols, mg
- flavones, mg
- anthocyanins, mg
- isoflavonoids, mg thirty
thirty
200
ten
fifty
2 Polymeric phenolic compounds, including condensed and hydrolysable tannins, mg 200 Stilbenes, mg 2 Dietary fiber, g:
lignin,
pectin,
polydextrose 25 L-carnitine, mg 300 Coenzyme Q10, mg thirty

Example 6

A specialized food product, which is a multicomponent dry mixture of essential nutrients, provides 50% of the daily norm of the physiological need for essential nutrients as part of a high-calorie version of the standard diet of adults undergoing inpatient treatment in medical organizations, the diet of social service recipients in a stationary form in social protection institutions, diet of workers employed in work with harmful working conditions.

Ingredient Content phenolic acids,
- hydroxybenzoic acids, mg
- hydroxycinnamic acids, mg 25
100 Dietary fiber, g:
Cellulose,
inulin,
polydextrose 3
5
4.5 L-carnitine, mg 150 Coenzyme Q10, mg fifteen

Example 7

A specialized food product, which is a multicomponent dry mixture of essential nutrients, provides 75% of the daily norm of the physiological need for essential nutrients as part of a high-calorie version of the standard diet of adults undergoing inpatient treatment in medical organizations, the diet of social service recipients in a stationary form in social protection institutions, diet of workers employed in work with harmful working conditions.

Ingredient Content phenolic acids,
- hydroxybenzoic acids, mg
- hydroxycinnamic acids, mg 37.5
125 Polymeric phenolic compounds, including condensed and hydrolysable tannins, mg 125 Dietary fiber, g:
chitin,
chitosan,
pectin 3.75
7
eight L-carnitine, mg 225 Coenzyme Q10, mg 22.5

Example 8

A specialized food product, which is a multicomponent dry mixture of essential nutrients, provides 65% of the daily norm of the physiological need of essential nutrients as part of a high-calorie version of the standard diet of adults undergoing inpatient treatment in medical organizations, the diet of social service recipients in a stationary form in social protection institutions, diet of workers employed in work with harmful working conditions.

Ingredient Content phenolic acids,
- hydroxybenzoic acids, mg
- hydroxycinnamic acids, mg 32.5
130 Polymeric phenolic compounds, including condensed and hydrolysable tannins, mg 130 Stilbenes, mg 1.3 Dietary fiber, g:
hemicellulose,
gum 4.5
12 L-carnitine, mg 195 Coenzyme Q10, mg 19.5

Example 9

A specialized food product, which is a multicomponent dry mixture of essential nutrients, provides 80% of the daily norm of the physiological need for essential nutrients as part of a high-calorie version of the standard diet of adults undergoing inpatient treatment in medical organizations, the diet of social service recipients in a stationary form in social protection institutions, diet of workers employed in work with harmful working conditions.

Ingredient Content phenolic acids,
- hydroxybenzoic acids, mg fifty flavonoids,
- isoflavonoids, mg 1.6 Stilbenes, mg 1.6 Dietary fiber, g:
Chitin,
chitosan ten
ten L-carnitine, mg 240 Coenzyme Q10, mg 24

Example 10

A specialized food product, which is a multicomponent dry mixture of essential nutrients, provides 5% of the daily norm of the physiological need for essential nutrients as part of a high-calorie version of the standard diet of adults undergoing inpatient treatment in medical organizations, the diet of social service recipients in a stationary form in social protection institutions, diet of workers employed in work with harmful working conditions.

Ingredient Content Flavonoids
- flavonols, mg
- flavanones, mg
- flavan-3-ols, mg
- flavones, mg
- anthocyanins, mg
- isoflavonoids, mg 1.5
1.5
ten
0.5
2.5
0.1 Dietary fiber, g:
gum 1.25 L-carnitine, mg fifteen Coenzyme Q10, mg 1.5

Example 11

A specialized food product, which is a multi-component dry mixture of essential nutrients, provides 25% of the daily norm of the physiological need of essential nutrients as part of a high-calorie version of the standard diet of adults undergoing inpatient treatment in medical organizations, the diet of social service recipients in a stationary form in social protection institutions, diet of workers employed in work with harmful working conditions.

Ingredient Content flavonoids,
- flavonols, mg
- flavanones, mg
- flavan-3-ols, mg
- flavones, mg
- anthocyanins, mg
- isoflavonoids, mg 7.5
7.5
fifty
2.5
12.5
0.5 Polymeric phenolic compounds, including condensed and hydrolysable tannins, mg fifty Stilbenes, mg 0.5 Dietary fiber, g:
resistant starch 6.25 L-carnitine, mg 75 Coenzyme Q10, mg 7.5

Example 12

A specialized food product, which is a multicomponent dry mixture of essential nutrients, provides 100% of the daily norm of the physiological need of essential nutrients as part of a high-calorie version of the standard diet of adults undergoing inpatient treatment in medical organizations, the diet of social service recipients in a stationary form in social protection institutions, diet of workers employed in work with harmful working conditions.

Ingredient Content polymeric phenolic compounds,
- condensed and hydrolysable tannins, mg 200 Stilbenes, mg 2 Dietary fiber, g:
β-glucan,
pectin,
resistant starch 5
fifteen
5 L-carnitine, mg 300 Coenzyme Q10, mg thirty

Example 13

A specialized food product, which is a multicomponent dry mixture of essential nutrients, provides 150% of the daily norm of the physiological need of essential nutrients as part of a high-calorie version of the standard diet of adults undergoing inpatient treatment in medical organizations, the diet of social service recipients in a stationary form in social protection institutions, diet of workers employed in work with harmful working conditions.

Ingredient Content phenolic acids,
- hydroxybenzoic acids, mg
- hydroxycinnamic acids, mg fifty
200 flavonoids,
- flavonols, mg
- flavanones, mg
- flavan-3-ols, mg
- flavones, mg
- anthocyanins, mg
- isoflavonoids, mg 45
45
300
fifteen
75
3 Stilbenes, mg 3 Dietary fiber, g:
β-glucan,
pectin,
resistant starch,
gum ten
ten
ten
7.5 L-carnitine, mg 400 Coenzyme Q10, mg 45

Example 14

A specialized food product, which is a multicomponent dry mixture of essential nutrients, provides 10% of the daily norm of the physiological need of essential nutrients as part of a high-calorie version of the standard diet of adults undergoing inpatient treatment in medical organizations, the diet of social service recipients in a stationary form in social protection institutions, diet of workers employed in work with harmful working conditions.

Ingredient Content phenolic acids,
- hydroxycinnamic acids, mg twenty flavonoids,
- anthocyanins, mg 5 Polymeric phenolic compounds, including condensed and hydrolysable tannins, mg twenty Dietary fiber, g:
hemicellulose, g 2.5 L-carnitine, mg thirty Coenzyme Q10, mg 3

Example 15

A specialized food product, which is a multi-component dry mixture of essential nutrients, provides 200% of the daily norm of the physiological need of essential nutrients as part of a high-calorie version of the standard diet of adults undergoing inpatient treatment in medical organizations, the diet of social service recipients in a stationary form in social protection institutions, diet of workers employed in work with harmful working conditions.

Ingredient Content phenolic acids,
- hydroxybenzoic acids, mg
- hydroxycinnamic acids, mg 100
400 flavonoids,
- flavonols, mg
- flavanones, mg
- flavan-3-ols, mg
- flavones, mg
- anthocyanins, mg
- isoflavonoids, mg 60
60
400
twenty
100
four Polymeric phenolic compounds, including condensed and hydrolysable tannins, mg 400 Stilbenes, mg four Dietary fiber, g:
cellulose,
hemicellulose,
chitin,
β-glucan,
inulin,
oligofructose,
fructooligosaccharide,
lignin,
polydextrose, g
gum 5
5
5
5
5
5
5
5
5
5 L-carnitine, mg 600 Coenzyme Q10, mg 60

Example 16. Results of application of a specialized product obtained according to examples 1-15

Confirmation of the effectiveness and safety of the use of a specialized food product was obtained in the course of the study.

The study included 30 obese patients, including 13 men and 17 women, aged 32 to 45 years (mean age 42.1±4.8 years) in accordance with the inclusion and exclusion criteria. At the time of the initial examination in patients with obesity, the body mass index (BMI) averaged 40.9±4.05 kg/m ² , waist circumference (WC) - 114.9±10.1 cm. The average value of the WC suggests the presence of abdominal obesity in the majority of patients included in the study. The level of systolic blood pressure (SBP) averaged 135.9±6.87 mm Hg, diastolic - 85.1±4.4 mm Hg. Of the comorbidities in the patients included in the study, arterial hypertension, diseases of the digestive system, including chronic gastritis, chronic non-calculous cholecystitis, non-alcoholic fatty liver disease in the stage of fatty hepatosis were detected. All chronic diseases were in remission.

The effectiveness of the inclusion of a specialized food product in a standard low-calorie diet (NCD) was evaluated based on the results reflecting the dynamics of anthropometric indicators: body weight, BMI, WC; indicators of lipid metabolism: total cholesterol (CH), low-density lipoprotein (LDL) cholesterol, triglycerides (TG); antioxidant status: malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GP).

Patients with obesity were randomly divided into 2 groups of the same type: the main group and the comparison group of 15 people. in each, depending on the reduced calorie diet option used. In the main group, obese patients received NAC _o with the inclusion of the studied specialized food product; in the comparison group - NKD, which does not contain sources of phenolic compounds, L-carnitine, coenzyme Q10 and dietary fiber. The duration of the use of NKD _o and NKD was 14 days.

The applied dietary rations in terms of nutrient content, energy value and a set of food products included in their composition met the requirements of the orders of the Ministry of Health of Russia dated 05.08.2003 No. 330 "On measures to improve therapeutic nutrition in medical institutions of the Russian Federation" and from June 21, 2013 No. 395n "On approval of the norms of clinical nutrition."

Written informed consent was obtained from all study participants.

Research results

All patients of the main group noted good tolerance of the standard low-calorie diet with the inclusion of the studied specialized food product. For the entire period of clinical observations, not a single case of intolerance, dyspepsia, allergic reactions and other undesirable effects was noted when using NKD _o with the inclusion of the studied specialized food product.

The results of the study showed that, unlike patients of the comparison group, patients of the main group who received the studied specialized food product showed a more pronounced tendency to decrease in body weight compared to that of patients in the comparison group (Table 1).

Table 1 - Dynamics of body weight, BMI and WC in patients with obesity under the influence of a low-calorie NCI diet _about (M±m)

Indicators Main group Comparison group Body weight, kg
before taking the product
after taking the product 117.9±9.92
111.8±5.1* 116.1±9.61
111.1±9.34* BMI, kg / m ²
before taking the product
after taking the product 41.2±4.25
39.5±3.15* 40.9±4.05
39.5±3.23* OT, cm
before taking the product
after taking the product 115.8±9.81
111.7±9.42* 114.7±10.1
110.9±9.89*

Here and below: 1 – before treatment; 2 - after the course of treatment; * - p<0.05 - compared with the baseline.

From the presented Table 1 it follows that in patients of the main group, a statistically significant decrease in body weight, BMI and WC was 5.2%, 4.1% and 3.6%, respectively, in patients of the comparison group - 4.2%, 3 .4% and 3.3% respectively. from the original level.

In table. Figure 2 shows the dynamics of blood lipid parameters in obese patients under the influence of a low-calorie diet variant of the NKD _o .

Table 2 - Blood lipid parameters in obese patients under the influence of a low-calorie NCI diet _about (M±m)

Indicators Main group Comparison group Total cholesterol, mmol/l
before taking the product
after taking the product 5.41±0.31
4.83±0.23* 5.33±0.21
4.91±0.22 LDL cholesterol, mmol/l
before taking the product
after taking the product 3.94±0.29
3.54±0.21* 3.89±0.37
3.64±0.41 TG, mmol/l
before taking the product
after taking the product 1.52±0.12
1.21±1.22* 1.41±0.14
1.28±0.06

From the data presented in table. 2, it follows that in the course of treatment in patients with obesity who received a low-calorie diet NCI _o , there was a statistically significant decrease in the content of total cholesterol in the blood serum (by an average of 10.7% of the initial level, p<0.05), LDL-C (by an average of 10.2%, p<0.05) m TG (by an average of 20.4%, p<0.05). In patients of the comparison group, the decrease in the content of total cholesterol and LDL cholesterol was less pronounced and unreliable.

Dynamics of antioxidant status indicators in obese patients under the influence of a low-calorie diet of NKD _o is presented in Table 3.

Table 3 - Dynamics of antioxidant status indicators in obese patients under the influence of a low-calorie NCI diet _about (M±m)

Indicators Main group Comparison group MDA, nmol/ml
before taking the product
after taking the product 2.97±0.06
2.46±0.15* 2.87±0.09
2.81±0.12 SOD, ng/ml
before taking the product
after taking the product 47.7±4.84
56.3±15.4* 47.5±5.43
48.3±4.06 GP, ng/ml
before taking the product
after taking the product 174.2±7.13
195.2±7.58* 174.5±7.13
186.2±10.1

From Table. 3 it follows that the inclusion of the studied product in a low-calorie diet was accompanied by a statistically significant decrease in the content of MDA in the blood serum by an average of 17.2% from the initial level (p<0.05). The dynamics of the level of MDA in blood serum in patients of the comparison group was less pronounced and not statistically significant.

The inclusion of the studied product in the low-calorie version of the standard diet was also accompanied by a statistically significant increase in the activity of SOD and GP in the blood serum by an average of 18.0% and 12.1% of the initial level, respectively. in the absence of significant differences in the dynamics of SOD and GP activity in patients of the comparison group.

Thus, the results of the study showed that the inclusion of the studied product in the NCI is accompanied by a fairly pronounced hypolipidemic effect in obese patients, which manifests itself in a statistically significant decrease in the content of total cholesterol, LDL cholesterol and triglycerides in the blood serum, combined with a tendency to a more pronounced decrease in indicators. body weight in these patients.

Thus, a technical result is achieved, which consists in restoring the functions of the body disturbed or lost as a result of the disease, preventing these disorders, as well as increasing the adaptive capabilities of the body.

Example 17 Results of application of a specialized product obtained according to example 1-15

Confirmation of the efficacy and safety of the use of a specialized food product in patients with type 2 diabetes mellitus (DM) receiving oral hypoglycemic therapy was obtained in the course of the study.

The study included 30 patients with type 2 diabetes, including 7 men and 23 women, aged 35 to 69 years (mean age 59.8±5.1 years) in accordance with the inclusion and exclusion criteria. At the time of the initial examination, the body mass index (BMI) on average for the entire group was 40.1±3.94 kg/m ² , waist circumference (WC) - 114.5±11.0 cm. The average value of the WC suggests the presence of abdominal obesity in the majority of patients included in the study. All patients with type 2 diabetes were diagnosed with stage 1-2 arterial hypertension: systolic blood pressure (SBP) averaged 140.9 ± 6.89 mm Hg, diastolic - 90.9 ± 5.25 mm Hg. . Of the comorbidities in the patients included in the study, coronary heart disease, diseases of the digestive system (chronic gastritis, chronic non-calculous cholecystitis, non-alcoholic fatty liver disease in the stage of fatty hepatosis), kidney disease (urolithiasis, chronic pyelonephritis), chronic lung diseases (chronic obstructive pulmonary disease, bronchial asthma). All chronic diseases were in remission.

The effectiveness of the inclusion of a specialized food product in a standard low-calorie diet (NCD) was evaluated based on the results reflecting the dynamics of anthropometric indicators: body weight, BMI, WC; SBP level; indicators of lipid metabolism: total cholesterol (CH), low-density lipoprotein (LDL) cholesterol, triglycerides (TG); functional state of the liver: activity of alanine and aspratate aminotransferases, gamma-glutamyl transferase (ALAT, ASAT, GGTP); indicators of antioxidant status: diene conjugates (DC), malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GP).

Patients with type 2 diabetes receiving oral hypoglycemic therapy were randomly divided into 2 similar groups: the main group and the comparison group of 15 people each, depending on the low-calorie diet option used. In the main group, patients with type 2 DM received NAC _DM with the inclusion of the studied specialized food product; in the comparison group - NKD, which does not contain sources of phenolic compounds, L-carnitine, coenzyme Q10 and dietary fiber. The duration of the use of NKD _sd and NKD was 14 days.

The used dietary rations in terms of nutrient content, energy value and a set of food products included in their composition met the requirements of the orders of the Ministry of Health of Russia dated 05.08.2003 No. 330 "On measures to improve therapeutic nutrition in medical institutions of the Russian Federation" and from June 21, 2013 No. 395n "On approval of the norms of clinical nutrition."

Written informed consent was obtained from all study participants.

Research results

All patients of the main group noted good tolerance of the standard low-calorie diet with the inclusion of the studied specialized food product. For the entire period of clinical observations, not a single case of intolerance, dyspepsia, allergic reactions and other undesirable effects was noted when using NCD _sd with the inclusion of the studied specialized food product.

The results of the study showed that in patients of the main group who received the studied specialized food product, there was a more pronounced trend towards a decrease in body weight and SBP levels compared to that in patients of the comparison group (Table 4).

Table 4 - Dynamics of body weight, BMI, WC and SBP in patients with type 2 diabetes receiving oral hypoglycemic therapy under the influence of a low-calorie NCI diet _sd (M±m)

Indicators Main group Comparison group Body weight, kg
before taking the product
after taking the product 115.3±5.43
109.8±4.52* 114.9±3.96
110.1±4.37* BMI, kg / m ²
before taking the product
after taking the product 40.6±4.12
38.9±3.34* 40.1±4.01
38.6±3.42* OT, cm
before taking the product
after taking the product 114.5±10.3
109.9±10.1* 113.9±10.1
109.8±10.5* GARDEN, mm R.St.
before taking the product
after taking the product 141.1±8.79
135.1±8.31* 140.8±7.79
135.7±8.71*

Here and below: 1 – before treatment; 2 - after the course of treatment; * - p<0.05 - compared with the baseline.

From the presented Table 4 it follows that in patients of the main group, a statistically significant decrease in body weight, BMI and WC was 4.8%, 4.2% and 4.0%, respectively, in patients of the comparison group - 4.2%, 3 .7% and 3.6%, respectively, from the initial level. The degree of SBP reduction in type 2 DM patients who received the NCI diet _diet averaged 4.1% of the baseline (p<0.05); in the comparison group - an average of 3.6% (p<0.05).

In table. Figure 5 shows the dynamics of blood lipid parameters in patients with type 2 diabetes receiving oral hypoglycemic therapy under the influence of a diet with a reduced caloric content of NCD _sd .

Table 5 - Blood lipid parameters in patients with type 2 diabetes receiving oral hypoglycemic therapy under the influence of a low-calorie NCI diet _sd (M±m)

Indicators Main group Comparison group Total cholesterol, mmol/l
before taking the product
after taking the product 5.84±0.37
4.79±0.23* 5.89±0.15
4.93±0.36* LDL cholesterol, mmol/l
before taking the product
after taking the product 3.73±0.25
2.93±0.21* 3.42±0.38
3.29±0.36 TG, mmol/l
before taking the product
after taking the product 2.16±0.17
1.69±0.18* 2.14±0.15
1.73±0.16*

From the data presented in table. 5, it follows that in the process of diet therapy in patients of the main group, a significant decrease in the content of total cholesterol, LDL cholesterol and triglycerides in the blood serum from the initial level was noted (on average by 17.8%, 21.4% and 21.8% respectively) , in patients of the comparison group - a significant decrease in the content of total cholesterol and triglycerides (on average by 16.3% and 19.2 respectively). In patients of the comparison group, the decrease in LDL cholesterol was less pronounced and unreliable.

In table. Figure 6 shows the dynamics of indicators of the functional state of the liver in patients with type 2 diabetes receiving oral hypoglycemic therapy, under the influence of a diet with a reduced caloric content of the NCD _sd .

Table 6 - Indicators of the functional state of the liver in patients with type 2 diabetes receiving oral hypoglycemic therapy, under the influence of a low-calorie diet NCI _sd (M±m)

Indicators Main group Comparison group ALAT, IU/l
before taking the product
after taking the product 32.7±2.11
22.1±2.12* 33.3±2.47
29.9±2.46 ASAT, IU/l
before taking the product
after taking the product 31.6±1.94
20.9±1.91* 32.4±1.73
30.0±1.62 GGTP, U/l
before taking the product
after taking the product 25.1±2.19
22.3±2.11* 24.6±2.17
25.6±2.23

From the data presented in Table 6, it follows that in the main group there was a statistically significant decrease in the activity of ALAT, ASAT and GGTP in patients with type 2 diabetes who received a low-calorie diet of _NKD DM against the background of oral hypoglycemic therapy, on average by 32.4%, 33.7% and 36.5% of baseline (p<0.05). In patients of the comparison group, the dynamics of the activity of ALAT, ASAT and GGTP was less pronounced and not statistically significant.

The dynamics of antioxidant status in patients with type 2 diabetes receiving oral hypoglycemic therapy, under the influence of a low-calorie diet NKD _o is presented in Table 7.

Table 7 - Dynamics of antioxidant status indicators in patients with type 2 diabetes receiving oral hypoglycemic therapy, under the influence of a low-calorie NCI diet _sd (M±m)

Indicators Main group Comparison group DC, nmol/ml
before taking the product
after taking the product 5.11±0.32
3.98±0.31* 4.45±0.55
4.28±0.42 MDA, nmol/ml
before taking the product
after taking the product 4.22±0.44
2.45±0.22* 4.45±0.46
3.85±0.33 MDA-oxLDL, mcg/ml
before taking the product
after taking the product 1.73±0.11
1.31±0.11* 1.46±0.12
1.32±0.12 SOD, ng/ml
before taking the product
after taking the product 41.7±2.28
58.6±4.11* 41.4±4.53
43.3±5.01 GP, ng/ml
before taking the product
after taking the product 164.2±7.23
196.2±8.18* 176.4±7.23
185.3±11.2

From Table. It follows from Table 7 that in the course of treatment in patients of the main group who received a low-calorie NCDd diet against the background of oral hypoglycemic therapy, there was a statistically significant decrease in the content of DC, MDA and MDA-oxLDL in the blood serum by an average of 22.1%, 34.7% and 24.3% of baseline resp. (p<0.05). The dynamics of the content of DC, MDA and MDA-oxLDL in the blood serum of patients in the comparison group was less pronounced and not statistically significant.

Inclusion in the low-calorie version of the standard diet of the study product was accompanied by a statistically significant increase in the activity of SOD and GP in the blood serum in patients with type 2 diabetes who received oral hypoglycemic therapy, by an average of 40.5% and 19.5% of the initial level, respectively. (p<0.05) in the absence of significant differences in the dynamics of SOD and GP activity in patients of the comparison group.

Thus, the results of the study showed that the inclusion of the study product in the NCI is accompanied by a fairly pronounced hypolipidemic effect in patients with type 2 diabetes who received oral hypoglycemic therapy, which manifests itself in a statistically significant decrease in the content of total cholesterol, LDL cholesterol and triglycerides in the blood serum, combined with a tendency to a more pronounced decrease in body weight and SBP in these patients. At the same time, an improvement in the functional state of the liver was noted, manifested in a statistically significant decrease in the activity of ALAT, ASAT and GGTP in the blood serum in patients of the main group who received oral hypoglycemic therapy. Inclusion of the studied product in the NCI is accompanied by an increase in the antioxidant effect of complex therapy, which manifests itself in a statistically significant decrease in the content of DC, MDA and MDA-oxLDL, as well as in an increase in the activity of SOD and GP in the blood serum in patients of the main group in the absence of significant differences in the dynamics of antioxidant parameters. status in patients of comparison groups.

Example 18 - Results of application of a specialty food product obtained according to examples 1-15

Confirmation of the efficacy and safety of the use of a specialized food product in patients with type 2 diabetes mellitus (DM) receiving insulin therapy was obtained in the course of the study.

The study included 30 patients with type 2 diabetes, including 6 men and 24 women, aged 37 to 69 years (mean age 59.9±5.8 years) in accordance with the inclusion and exclusion criteria. At the time of the initial examination, the body mass index (BMI) on average for the entire group was 39.4±3.79 kg/m ² , waist circumference (WC) - 112.4±10.9 cm. obesity in the majority of patients included in the study. All patients with type 2 diabetes were diagnosed with stage 1-2 arterial hypertension: systolic blood pressure (SBP) averaged 140.8±7.84 mm Hg, diastolic - 91.7±5.67 mm Hg . Of the comorbidities in the patients included in the study, coronary heart disease, diseases of the digestive system (chronic gastritis, chronic non-calculous cholecystitis, non-alcoholic fatty liver disease in the stage of fatty hepatosis), kidney disease (urolithiasis, chronic pyelonephritis), chronic lung diseases (chronic obstructive pulmonary disease, bronchial asthma). All chronic diseases were in remission.

The effectiveness of the inclusion of a specialized food product in a standard high-protein diet (HPA) was assessed based on the results reflecting the dynamics of anthropometric indicators: body weight, BMI, WC; SBP level; indicators of lipid metabolism: total cholesterol (CH), low-density lipoprotein (LDL) cholesterol, triglycerides (TG); functional state of the liver: activity of alanine and aspratate aminotransferases, gamma-glutamyl transferase (ALAT, ASAT, GGTP); indicators of antioxidant status: diene conjugates (DC), malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GP).

Patients with type 2 diabetes receiving insulin therapy were randomly divided into 2 groups of the same type: the main group and the comparison group of 15 people. in each, depending on the variant of the diet with an increased amount of protein (HAP). In the main group, type 2 DM patients received IAP _DM with the inclusion of the studied specialized food product; in the comparison group - IAP, which does not contain sources of phenolic compounds, L-carnitine, coenzyme Q10 and dietary fiber. The duration of the use of IAP _sd and IAP was 14 days.

The used dietary rations in terms of nutrient content, energy value and a set of food products included in their composition met the requirements of the orders of the Ministry of Health of Russia dated 05.08.2003 No. 330 "On measures to improve therapeutic nutrition in medical institutions of the Russian Federation" and from June 21, 2013 No. 395n "On approval of the norms of clinical nutrition."

The study protocol was approved by the ethics committee of the Therapeutic Nutrition Clinic of the Federal State Budget Institution "Federal Research Center for Nutrition and Biotechnology". Written informed consent was obtained from all study participants.

Research results

All patients of the main group noted good tolerance of the standard low-calorie diet with the inclusion of the studied specialized food product. For the entire period of clinical observations, there was not a single case of intolerance, dyspepsia, allergic reactions and other adverse events when using IAP _sd with the inclusion of the studied specialized food product.

The results of the study showed that in patients of the main group who received the studied specialized food product, there was a more pronounced trend towards a decrease in body weight and SBP levels compared to that in patients of the comparison group (Table 8).

Table 8 - Dynamics of body weight, BMI, WC and SBP in patients with type 2 diabetes receiving insulin therapy under the influence of a high-protein IAP diet _sd (M±m)

Indicators Main group Comparison group Body weight, kg
before taking the product
after taking the product 112.4±7.35
107.0±7.98* 112.0±5.86
107.6±5.97* BMI, kg / m ²
before taking the product
after taking the product 39.5±3.78
37.8±3.12* 39.2±3.81
37.7±3.67* OT, cm
before taking the product
after taking the product 112.6±10.2
107.7±10.7* 112.1±11.6
107.6±10.5* GARDEN, mm R.St.
before taking the product
after taking the product 141.0±7.91
135.0±7.37* 140.5±7.76
135.9±7.08*

Here and below: 1 – before treatment; 2 - after the course of treatment; * - p<0.05 - compared with the baseline.

From the presented Table 8, it follows that in patients of the main group who received a high-protein diet of IAP _SD with the inclusion of the test product on the background of insulin therapy, there was a statistically significant decrease in body weight, BMI and WC (by an average of 4.8%, 4.3% and 4.4% respectively), in patients of the comparison group - a statistically significant decrease in body weight, BMI and WC (on average by 3.9%, 3.8% and 4.0% respectively). The degree of SBP reduction in type 2 DM patients treated with the IAP DM diet averaged _4.3 % of the baseline (p<0.05); in the comparison group - an average of 3.3% (p<0.05).

In table. Figure 9 shows the dynamics of blood lipid parameters in patients with type 2 diabetes receiving insulin therapy under the influence of a high-protein diet of IAP _DM .

Table 9 - Blood lipid parameters in patients with type 2 diabetes receiving insulin therapy under the influence of a high-protein IAP diet _sd (M±m)

Indicators Main group Comparison group Total cholesterol, mmol/l
before taking the product
after taking the product 5.77±0.37
4.71±0.27* 5.62±0.39
4.89±0.37* LDL cholesterol, mmol/l
before taking the product
after taking the product 3.75±0.32
2.95±0.29* 3.69±0.38
3.23±0.31 TG, mmol/l
before taking the product
after taking the product 2.17±0.19
1.71±0.16* 2.18±0.21
1.95±0.23

From the data presented in table. 9, it follows that in the process of diet therapy in patients of the main group who received a high-protein diet of IAP _DM against the background of insulin therapy, a significant decrease in the content of total cholesterol, LDL cholesterol and triglycerides in the blood serum from the initial level was noted (on average by 18.3%, 21.3 % and 21.2% respectively), in patients of the comparison group - a significant decrease in the content of total cholesterol. In patients of the comparison group, the decrease in the content of LDL-C and TG was less pronounced and not statistically significant.

In table. 10 shows the dynamics of indicators of the functional state of the liver in patients with type 2 diabetes receiving insulin therapy under the influence of a high-protein diet of IAP _DM .

Table 10 - Indicators of the functional state of the liver in patients with type 2 diabetes receiving insulin therapy under the influence of a high-protein IAP diet _sd (M±m)

Indicators Main group Comparison group ALAT, IU/l
before taking the product
after taking the product 31.1±2.14
22.5±2.18* 34.7±3.31
29.8±3.22 ASAT, IU/l
before taking the product
after taking the product 32.7±1.9
23.3±2.6* 39.1±2.53
35.1±2.21 GGTP, U/l
before taking the product
after taking the product 27.1±2.23
21.3±2.21* 25.1±2.07
24.4±2.13

From the data presented in Table 10, it follows that in the main group there was a statistically significant decrease in the activity of ALAT, ASAT and GGTP in patients with type 2 diabetes who received a high-protein diet of IAP _DM against the background of insulin therapy, on average by 27.7%, 28, 7% and 21.4% of baseline (p<0.05). In patients of the comparison group, the dynamics of the activity of ALAT, ASAT and GGTP was less pronounced and not statistically significant.

The dynamics of antioxidant status in patients with type 2 diabetes receiving oral hypoglycemic therapy, under the influence of a low-calorie diet NKD _o is presented in Table 11.

Table 11 - Dynamics of antioxidant status indicators in patients with type 2 diabetes receiving insulin therapy under the influence of a high-protein IAP diet _sd (M±m)

Indicators Main group Comparison group DC, nmol/ml
before taking the product
after taking the product 5.23±0.41
3.94±0.32* 5.15±0.51
4.78±0.41 MDA, nmol/ml
before taking the product
after taking the product 4.31±0.34
2.66±0.21* 4.35±0.39
4.15±0.31 MDA-oxLDL, mcg/ml
before taking the product
after taking the product 1.84±0.11
1.35±0.12* 1.76±0.17
1.63±0.22 SOD, ng/ml
before taking the product
after taking the product 42.9±4.24
56.3±4.41* 43.6±4.23
47.9±3.96 GP, ng/ml
before taking the product
after taking the product 161.2±8.33
197.2±8.78* 164.5±8.13
176.2±8.01

From Table. 11 it follows that in the course of treatment in patients of the main group who received a high-protein diet of IAP DM against the background of insulin therapy, there was a statistically significant decrease in the content of DC, MDA and MDA- _oxLDL in the blood serum by an average of 24.7%, 38.3% and 26 ,6 from the initial level resp. (p<0.05). The dynamics of the content of DC, MDA and MDA-oxLDL in the blood serum of patients in the comparison group was less pronounced and not statistically significant.

The inclusion of the studied product in the high-protein IAP diet was accompanied by a statistically significant increase in the activity of SOD and GP in the blood serum in patients with type 2 diabetes who received insulin therapy, on average by 31.2% and 22.3% of the initial level, respectively. (p<0.05) in the absence of significant differences in the dynamics of SOD and GP activity in patients of the comparison group.

Thus, the results of the study showed that the inclusion of the studied product in the IAP is accompanied by a fairly pronounced hypolipidemic effect in patients with type 2 diabetes who received insulin therapy, which manifests itself in a statistically significant decrease in the content of total cholesterol, LDL cholesterol and triglycerides in the blood serum, combined with a tendency to a more pronounced decrease in body weight and SBP in these patients. At the same time, an improvement in the functional state of the liver was noted, manifested in a statistically significant decrease in the activity of ALAT, ASAT and GGTP in the blood serum in patients of the main group who received insulin therapy. The inclusion of the studied product in the IAP provides an increase in the antioxidant effect of complex therapy, which is manifested in a statistically significant decrease in the content of DC, MDA and MDA-oxLDL, as well as in an increase in the activity of SOD and GP in the blood serum of patients of the main group in the absence of significant differences in the dynamics of antioxidant parameters. status in patients of comparison groups.

Example 19 - Results of application of a specialty food product obtained according to examples 1-15

Confirmation of the efficacy and safety of using a specialized food product in patients with coronary heart disease (CHD) was obtained in the course of the study.

The study included 40 IHD patients, including 26 men and 14 women, aged 37 to 75 years (mean age 57.1±5.2 years) in accordance with the inclusion and exclusion criteria. The duration of the disease ranged from 5 to 15 years, averaging 10±2.3 years. At the time of the initial examination, the body mass index (BMI) on average for the entire group was 28.2±1.85 kg/m ² . Of the concomitant diseases in patients with coronary artery disease, arterial hypertension of 1-2 stages: systolic blood pressure (SBP) averaged 145.7±8.34 mm Hg, diastolic (DBP) - 93.9±7.56 mm Hg .st.; chronic diseases of the gastrointestinal tract (chronic gastritis, chronic non-calculous cholecystitis); kidney disease (urolithiasis, chronic pyelonephritis), chronic lung disease (chronic obstructive pulmonary disease, bronchial asthma). All chronic diseases were in remission and did not require intensive drug therapy.

The effectiveness of including a specialized food product in the main standard diet (SDA) variant was assessed by results reflecting SBP and DBP levels; indicators of lipid metabolism: total cholesterol (CH), low-density lipoprotein (LDL) cholesterol, triglycerides (TG); functional state of the liver: activity of alanine and aspratate aminotransferases, gamma-glutamyl transferase (ALAT, ASAT, GGTP); indicators of antioxidant status: diene conjugates (DC), malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GP).

IHD patients were randomly divided into 2 similar groups: the main group and the comparison group of 20 people each, depending on the main variant of the standard diet (ATD). In the main group, IHD patients received ATS _en with the inclusion of the studied specialized food product; in the comparison group - ATS, which does not contain sources of phenolic compounds, L-carnitine, coenzyme Q10 and dietary fiber. The duration of the use of OVD _en and OVD was 14 days.

The used dietary rations in terms of nutrient content, energy value and a set of food products included in their composition met the requirements of the orders of the Ministry of Health of Russia dated 05.08.2003 No. 330 "On measures to improve therapeutic nutrition in medical institutions of the Russian Federation" and from June 21, 2013 No. 395n "On approval of the norms of clinical nutrition."

Written informed consent was obtained from all study participants.

Research results

All patients of the main group noted good tolerance of the main variant of the standard diet with the inclusion of the studied specialized food product. For the entire period of clinical observations, there was not a single case of intolerance, dyspepsia, allergic reactions and other adverse events when using IAP _sd with the inclusion of the studied specialized food product.

The results of the study showed that in patients of the main group who received the main version of the standard diet of ATS _en with the inclusion of the product under study, there was a statistically significant decrease in the level of SBP and DBP compared with that in patients of the comparison group (Table 12).

Table 12 - Dynamics of SBP and DBP in patients with coronary artery disease under the influence of the main variant of the standard ATS diet _en (M±m)

Indicators Main group Comparison group GARDEN, mm R.St.
before taking the product
after taking the product 145.9±8.34
135.0±7.37* 144.8±8.65
139.1±8.76 DBP, mm R.St.
before taking the product
after taking the product 93.9±7.56
88.1±6.57* 92.6±6.78
90.2±7.89

Here and below: 1 – before treatment; 2 - after the course of treatment; * - p<0.05 - compared with the baseline.

From the presented table it follows that in patients of the main group who received the main variant of the standard diet OVD _en with the inclusion of the test product, there was a statistically significant decrease in the level of SBP and DBP by an average of 7.5% and 6.2% respectively (p< 0.05), while in patients of the comparison group, the dynamics of SBP and DBP was less pronounced and not statistically significant.

In table. 13 shows the dynamics of blood lipid parameters in patients with coronary artery disease under the influence of the main variant of the standard diet of ATS _en .

Table 13 - Blood lipid parameters in patients with coronary artery disease under the influence of the main variant of the standard ATS diet _en (M±m)

Indicators Main group Comparison group Total cholesterol, mmol/l
before taking the product
after taking the product 5.98±0.44
4.75±0.39* 5.82±0.39
5.05±0.37* LDL cholesterol, mmol/l
before taking the product
after taking the product 3.95±0.37
2.89±0.23* 3.89±0.31
3.43±0.33 TG, mmol/l
before taking the product
after taking the product 2.27±0.21
1.61±0.19* 2.18±0.21
1.95±0.23

From the data presented in table. 13, it follows that in the process of diet therapy in patients of the main group who received the main version of the standard diet of ATS _en , a statistically significant decrease in the content of total cholesterol, LDL cholesterol and triglycerides in the blood serum from the initial level was noted (on average by 20.6%, 26.8 % and 29.1%, respectively, p<0.05), in patients of the comparison group - a significant decrease in the content of total cholesterol (on average by 13.2%, p<0.05). In patients of the comparison group, a decrease in the content of LDL cholesterol and TG was less pronounced and not statistically significant.

In table. 14 shows the dynamics of indicators of the functional state of the liver in patients with coronary artery disease under the influence of the main variant of the standard diet of ATS _en .

Table 14 - Indicators of the functional state of the liver in patients with coronary artery disease under the influence of the main variant of the standard ATS diet _en (M±m)

Indicators Main group Comparison group ALAT, IU/l
before taking the product
after taking the product 32.0±3.11
23.8±2.19* 33.8±3.41
31.9±3.32 ASAT, IU/l
before taking the product
after taking the product 33.8±2.45
24.5±2.36* 35.1±3.51
33.5±3.67 GGTP, U/l
before taking the product
after taking the product 29.1±2.34
22.4±2.13* 27.1±2.17
25.9±2.23

From the data presented in Table 14, it follows that in the main group there was a statistically significant decrease in the activity of ALAT, ASAT and GGTP in patients with type 2 diabetes who received the main variant of the standard diet of ATS _en by an average of 25.7%, 27.5% and 23.0% of baseline (p<0.05). In patients of the comparison group, the dynamics of the activity of ALAT, ASAT and GGTP was less pronounced and not statistically significant.

The dynamics of antioxidant status in patients with coronary artery disease under the influence of the main variant of the standard diet of ATS _en is presented in Table 15.

Table 15 - Dynamics of antioxidant status indicators in patients with coronary artery disease under the influence of the main variant of the standard ATS diet _en (M±m)

Indicators Main group Comparison group DC, nmol/ml
before taking the product
after taking the product 5.34±0.46
3.85±0.35* 5.23±0.52
4.89±0.47 MDA, nmol/ml
before taking the product
after taking the product 4.56±0.45
2.76±0.25* 4.35±0.39
4.15±0.31 MDA-oxLDL, mcg/ml
before taking the product
after taking the product 1.94±0.12
1.31±0.11* 1.86±0.18
1.61±0.16 SOD, ng/ml
before taking the product
after taking the product 41.9±4.12
57.8±5.31* 44.1±4.14
48.19±4.86 GP, ng/ml
before taking the product
after taking the product 158.3±11.3
197.1±11.8* 161.6±16.1
171.9±11.0

From Table. 15 it follows that in the course of treatment in patients of the main group who received the main variant of the OVD _en diet against the background of insulin therapy, there was a statistically significant decrease in the content of DC, MDA and MDA-oxLDL in the blood serum by an average of 25.5%, 39.5% and 32.5% of baseline resp. (p<0.05). The dynamics of the content of DC, MDA and MDA-oxLDL in the blood serum of patients in the comparison group was less pronounced and not statistically significant.

The inclusion of the study product in the main variant of the ATS _diet was accompanied by a statistically significant increase in the activity of SOD and GP in the blood serum of patients with type 2 diabetes who received insulin therapy, on average by 37.9% and 24.5% of the initial level, respectively. (p<0.05) in the absence of significant differences in the dynamics of SOD and GP activity in patients of the comparison group.

Thus, the results of the study showed that the inclusion of the studied product in the main version of the standard diet is accompanied by a fairly pronounced hypolipidemic effect in patients with coronary artery disease, which manifests itself in a statistically significant decrease in the content of total cholesterol, LDL cholesterol and TG in the blood serum, combined with a significant decrease in the level of SBP. and DBP in these patients. At the same time, an improvement in the indicators of the functional state of the liver was noted, manifested in a statistically significant decrease in the activity of ALAT, ASAT and GGTP in the blood serum in patients of the main group under the influence of the main variant of the standard OVD _en diet. The inclusion of the studied product in the ATS provides an increase in the antioxidant effect of complex therapy, which is manifested in a statistically significant decrease in the content of DC, MDA and MDA-oxLDL, as well as in an increase in the activity of SOD and GP in the blood serum of patients of the main group in the absence of significant differences in the dynamics of antioxidant parameters. status in patients of comparison groups.

Thus, only the composition of a specialized food product developed by us made it possible to achieve the preservation of positive biochemical effects in patients, bring blood glucose values closer to normal, as well as the amount of body fat as such, while maintaining normal intestinal microbiota.

Thus, a technical result is achieved, which consists in restoring the functions of the body disturbed or lost as a result of the disease, preventing these disorders, as well as increasing the adaptive capabilities of the body.

The specialized food product has a powder form, the advantages of which are due to the convenience of its introduction into the dishes of dietary therapeutic and dietary preventive nutrition 2-3 minutes before they are ready. The dry form of the product has a number of additional advantages related to transportation and storage, microbiological stability, which ensures long shelf life.

The content of essential biologically active substances in one daily portion of the product complies with the guidelines for adults undergoing inpatient treatment in medical organizations, recipients of social services in a stationary form in social protection institutions, workers employed in jobs with harmful working conditions.

The introduction of a specialized food product of a mixture of essential nutrients, a multicomponent dry mixture, into the dishes of dietary therapeutic and dietary preventive nutrition for adults who are hospitalized in medical organizations, recipients of social services in a stationary form in social protection institutions and workers employed in jobs with harmful working conditions, as The component of preparing ready-made meals allows you to have a positive impact on the functions of the body that have been disturbed or lost as a result of diseases and pathological conditions, to ensure the prevention of these disorders, and to increase the adaptive capabilities of the body.

Claims (17)

1. A specialized food product for dietary therapeutic and dietary preventive nutrition, which is a multicomponent dry mixture of essential nutrients, characterized in that it contains: phenolic compounds selected from the group consisting of phenolic acids and/or flavonoids and/or polymeric phenolic compounds and/or stilbenes in an amount of 5 to 200% of their normal physiological requirements for adults; dietary fiber selected from the group consisting of cellulose and/or hemicellulose and/or chitin and/or chitosan and/or β-glucans and/or gum and/or inulin and/or oligofructose and/ or fructooligosaccharides, and/or lignin, and/or pectins, and/or polydextrose, and/or resistant dextins, and/or resistant starches, in an amount of 5 to 200% of their normal physiological requirements for adults; L-carnitine, in an amount of 5 to 200% of their normal physiological requirements for adults; Coenzyme Q10 in an amount of 5 to 200% of their normal physiological requirements for adults. 2. Specialized food product according to claim 1, characterized in that the phenolic compounds selected from the group consisting of phenolic acids and/or flavonoids and/or polymeric phenolic compounds and/or stilbenes are contained in an amount of from 0.2 to 1548 mg. 3. Specialized food product according to claim 1, characterized in that dietary fibers selected from the group consisting of cellulose and/or hemicellulose and/or chitin and/or chitosan and/or β-glucans and/or gums, and/or inulin, and/or oligofructose, and/or fructooligosaccharides, and/or lignin, and/or pectins, and/or polydextrose, and/or resistant dextins, and/or resistant starches, be contained in an amount of 1, 25 to 50 g. 4. Specialized food product according to claim 1, characterized in that L-carnitine is contained in an amount of from 15 to 600 mg. 5. Specialized food product according to claim 1, characterized in that coenzyme Q10 is contained in an amount of from 1.5 to 60 mg. 6. A specialized food product according to claim 1, characterized in that the proposed product contains hydroxybenzoic acid in an amount of 5 to 100 mg and/or hydroxycinnamic acid in an amount of 20 to 400 mg as phenolic acids. 7. Specialized food product according to claim 1, characterized in that as flavonoids the proposed product contains flavonols in an amount of 3 to 60 mg and/or flavanones in an amount of 3 to 60 mg, and/or flavan-3-ols in an amount from 20 to 400 mg, and/or flavones in an amount from 1 to 20 mg, and/or anthocyanins in an amount from 5 to 100 mg, and/or isoflavones in an amount from 0.2 to 4 mg. 8. A specialized food product according to claim 1, characterized in that the proposed product contains condensed and hydrolyzable tannins in the amount of 20 to 400 mg as polymeric phenolic compounds. 9. Specialized food product according to claim 1, characterized in that the proposed product contains stilbenes in an amount of 0.2 to 4 mg. 10. Specialized food product according to claims 1 to 9, characterized in that it can be used for dietary therapeutic and dietary preventive nutrition of adults. 11. A specialized food product according to claims 1 to 9, characterized in that it additionally contains compounds of a protein and/or carbohydrate and/or fatty nature, and/or vitamins and vitamin-like compounds, and/or minerals, and/or other biologically active substances and/or food additives and/or flavors and/or processing aids, including those selected from the group of antioxidants and/or defoamers and/or sweeteners and/or fillers and/or carriers, and / or stabilizers and / or anti-caking agents, and / or naturally present in the raw material source of the biologically active substance that is part of the product. 12. A specialized food product according to claims 1 to 9, characterized in that it can be used in standard diets for catering for adults in medical organizations, in social protection institutions and working in harmful or especially harmful conditions. 13. A method for preparing dietary therapeutic and dietary preventive nutrition, characterized in that the specialized food product according to claims 1-12 is introduced during the preparation of dietary therapeutic and dietary preventive nutrition in an amount that ensures the introduction of 5 to 200% of the norm into the daily diet physiological needs of essential biologically active substances - phenolic compounds, dietary fiber, L-carnitine and coenzyme Q10, then mixed in the mass of the dish.